| Literature DB >> 32117796 |
Lvjie Xu1, Wen Jiang2, Hao Jia1, Lishu Zheng3, Jianguo Xing4, Ailin Liu1, Guanhua Du1.
Abstract
Influenza A virus (IAV) is a threat to public health due to its high mutation rate and resistance to existing drugs. In this investigation, 15 targets selected from an influenza virus-host interaction network were successfully constructed as a multitarget virtual screening system for new drug discovery against IAV using Naïve Bayesian, recursive partitioning, and CDOCKER methods. The predictive accuracies of the models were evaluated using training sets and test sets. The system was then used to predict active constituents of Compound Yizhihao (CYZH), a Chinese medicinal compound used to treat influenza. Twenty-eight compounds with multitarget activities were selected for subsequent in vitro evaluation. Of the four compounds predicted to be active on neuraminidase (NA), chlorogenic acid, and orientin showed inhibitory activity in vitro. Linarin, sinensetin, cedar acid, isoliquiritigenin, sinigrin, luteolin, chlorogenic acid, orientin, epigoitrin, and rupestonic acid exhibited significant effects on TNF-α expression, which is almost consistent with predicted results. Results from a cytopathic effect (CPE) reduction assay revealed acacetin, indirubin, tryptanthrin, quercetin, luteolin, emodin, and apigenin had protective effects against wild-type strains of IAV. Quercetin, luteolin, and apigenin had good efficacy against resistant IAV strains in CPE reduction assays. Finally, with the aid of Gene Ontology biological process analysis, the potential mechanisms of CYZH action were revealed. In conclusion, a compound-protein interaction-prediction system was an efficient tool for the discovery of novel compounds against influenza, and the findings from CYZH provide important information for its usage and development.Entities:
Keywords: biological process analysis; compound yizhihao; in vitro evaluation; influenza A virus; multitarget; virtual screening
Mesh:
Substances:
Year: 2020 PMID: 32117796 PMCID: PMC7026480 DOI: 10.3389/fcimb.2020.00016
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Scheme for model construction, identification of potential anti-influenza ingredients, and elucidation of the mechanisms of CYZH, based on network pharmacology approaches.
Figure 2The workflow for the construction of multi-target models against IAV.
The name and classification of flu targets.
| Hemagglutinin | HA | Viral target | CDOCKER |
| Nucleoprotein | NP | Viral target | CDOCKER |
| Matrix protein 2 | M2 | Viral target | CDOCKER |
| Neuraminidase | NA | Viral target | NB & RP |
| RNA-directed RNA polymerase | RdRp | Viral target | NB & RP |
| Reverse transcriptase | RT | Viral target | NB & RP |
| Cdc2-like kninase 1 | CLK1 | Host cellular target assisting viral replication | NB & RP |
| Cdc2-like kninase 4 | CLK4 | Host cellular target assisting viral replication | NB & RP |
| Opioid receptor | OPR | Neuroendocrine immunomodulation-related target | NB & RP |
| Dopamine receptor | D2R | Neuroendocrine immunomodulation-related target | NB & RP |
| N-methyl-D-aspartate receptor | NMDAR | Neuroendocrine immunomodulation-related target | NB & RP |
| Glutamate carboxypeptidase II | GCPII | Neuroendocrine immunomodulation-related target | NB & RP |
| Corticosteroid 11-beta-dehydrogenase | HSD11B1 | Neuroendocrine immunomodulation-related target | NB & RP |
| Tumor necrosis factor alpha | TNF-α | Neuroendocrine immunomodulation-related target | NB & RP |
| Nuclear factor of kappa B | NF-κB | Neuroendocrine immunomodulation-related target | NB & RP |
The detailed statistical description of data sets for flu targets.
| NA | 160 | 484 | 644 | 0.117 | 54 | 162 | 216 | 0.116 |
| RdRp | 166 | 498 | 664 | 0.111 | 55 | 165 | 220 | 0.113 |
| RT | 172 | 516 | 688 | 0.1 | 57 | 171 | 228 | 0.105 |
| CLK1 | 126 | 378 | 504 | 0.1 | 42 | 126 | 168 | 0.097 |
| CLK4 | 88 | 264 | 352 | 0.112 | 29 | 87 | 116 | 0.111 |
| OPR | 425 | 1,275 | 1,700 | 0.089 | 142 | 426 | 568 | 0.087 |
| D2R | 176 | 528 | 704 | 0.092 | 59 | 177 | 236 | 0.096 |
| NMDAR | 41 | 123 | 164 | 0.112 | 13 | 39 | 52 | 0.103 |
| GCPII | 118 | 354 | 472 | 0.108 | 39 | 117 | 156 | 0.108 |
| HSD11B1 | 1,900 | 5,700 | 7,600 | 0.096 | 633 | 1,899 | 2,532 | 0.097 |
| TNF-α | 878 | 2,634 | 3,512 | 0.102 | 293 | 879 | 1,172 | 0.098 |
| NF-κB | 848 | 2,544 | 3,392 | 0.084 | 282 | 846 | 1,128 | 0.086 |
The 5-fold validation and test set validation performance of 12 flu targets using NB and RP classifiers.
| NA | 1.000 | 1.000 | 0.967 | 0.981 | 0.977 | 1.000 | 0.965 | 0.917 |
| RdRp | 0.992 | 0.995 | 0.960 | 0.991 | 0.915 | 1.000 | 0.940 | 0.973 |
| RT | 0.992 | 0.996 | 0.800 | 0.969 | 0.891 | 0.993 | 0.327 | 0.779 |
| CLK1 | 0.974 | 0.990 | 0.854 | 0.981 | 0.954 | 0.993 | 0.769 | 0.917 |
| CLK4 | 0.992 | 0.999 | 0.954 | 0.978 | 1.000 | 1.000 | 0.809 | 0.961 |
| OPR | 0.983 | 0.998 | 0.901 | 0.994 | 0.995 | 1.000 | 0.868 | 0.983 |
| D2R | 0.989 | 0.997 | 0.895 | 0.994 | 0.978 | 1.000 | 0.868 | 0.978 |
| NMDAR | 0.984 | 0.999 | 0.884 | 0.994 | 0.648 | 1.000 | 0.648 | 1.000 |
| GCPII | 0.994 | 1.000 | 0.919 | 0.982 | 1.000 | 1.000 | 1.000 | 1.000 |
| HSD11B1 | 0.983 | 0.994 | 0.911 | 0.992 | 0.973 | 0.998 | 0.868 | 0.974 |
| TNF-α | 0.949 | 0.981 | 0.802 | 0.973 | 0.846 | 0.988 | 0.663 | 0.923 |
| NF-κB | 0.940 | 0.989 | 0.834 | 0.981 | 0.835 | 0.990 | 0.685 | 0.917 |
Figure 3Diagrams of the non-bonded interactions between the target protein and the co-crystallized ligands. (A,D) show the interaction between HA and o-sialic acid. N- [4-chloranyl-5- [4- [ [3-(2-methoxyphenyl)-5-methyl-1,2-oxazol-4-yl] carbonyl] piperazin-1-yl]−2-nitro-phenyl] pyridine-2-carboxamide shows powerful interactions with NP mainly through π-π T-shaped, π-π stacked, alkyl, and hydrogen bond interactions in (B,E). The non-bonded interactions between M2 and rimantadine (C,F) were strong with the key amino acid residues VAL27 and SER31.
Figure 4(A) Number of compounds corresponding to each target. (B) Proportion of compounds acting on different numbers of targets. (C) The network of 28 multitarget-directed ligands in CYZH and targets based on the prediction system against IAV. Blue circles represent drug nodes and red circles represent protein nodes.
The evaluation of the activity of constituents from CYZH based on an NA inhibition test (μM).
| Chlorogenic acid | 64.61 ± 6.97 | 57.15 ± 2.98 | N/A | N/A |
| Orientin | 53.71 ± 9.98 | 72.54 ± 2.97 | N/A | N/A |
| Epigoitrin | N/A | N/A | N/A | N/A |
| Rupestonic acid | N/A | N/A | N/A | N/A |
| Zanamivir | 0.0000176 ± 0.000013 | 0.000075 ± 0.000005 | 0.0000196 ± 0.0000074 | 0.0000913 ± 0.0000214 |
Data are expressed as mean ± SD (n = 3);
N/A: IC.
Figure 5Effect of CYZH compounds on TNF-α expression in virus-infected A549 cells. Data are expressed as mean±SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Model group.
The activity evaluation of constituents from CYZH in wild strains-induced CPE reduction assay (μM).
| Acacetin | 62 ± 5.91 | N/A | 77.44 ± 25.7 | N/A | N/A | 72.54 ± 11.74 | 12.46 ± 5.46 | 20.46 ± 0.86 |
| Indirubin | N/A | N/A | N/A | N/A | N/A | 52.58 ± 27.42 | N/A | N/A |
| Tryptanthrin | N/A | N/A | 72.01 ± 23.57 | N/A | N/A | 76.33 ± 3.4 | 17.74 ± 1.74 | 31.83 ± 11.56 |
| Quercetin | N/A | N/A | 8.59 ± 1.34 | 5.41 ± 0.14 | N/A | N/A | 9.99 ± 2.84 | 18.33 ± 3.52 |
| Luteolin | N/A | N/A | 4.53 ± 0.92 | 7.08 ± 0.3 | N/A | N/A | 44.69 ± 19.99 | N/A |
| Emodin | N/A | N/A | 55.85 ± 9.8 | 6.53 ± 0.29 | N/A | N/A | 18.24 ± 1.02 | 55.86 ± 6 |
| Apigenin | N/A | N/A | 16.69 ± 1.77 | 9.06 ± 0.41 | N/A | N/A | 9.28 ± 2.03 | 15.84 ± 1 |
| Oseltamivir | 83.44 ± 15.6 | 11.41 ± 7.44 | 74.89 ± 20.7 | 4.45 ± 0.24 | 77.94 ± 22.1 | 54.45 ± 14.24 | 6.25 ± 2.6 | 8.47 ± 1.73 |
| Ribavirin | 16.1 ± 1.47 | 47.51 ± 7.94 | 10.4 ± 2.19 | 16.35 ± 2.95 | 22.51 ± 6.16 | 62.45 ± 16.24 | 9.18 ± 0.99 | 21.65 ± 0.97 |
Data are expressed as mean ± SD (n = 3);
N/A: IC.
The activity evaluation of constituents from CYZH in resistant strains-induced CPE reduction assay (μM).
| Quercetin | N/A | 19.1 ± 1.95 | 6.93 ± 4.6 | 14.59 ± 1.8 | 20.73 ± 14.71 | 86.1 ± 13.83 | 7.73 ± 3.04 | 37.05 ± 18.16 |
| Luteolin | N/A | 47.17 ± 7.14 | 15.22 ± 4.46 | 20.13 ± 10.56 | 31.86 ± 1.99 | N/A | 1.14 ± 1.02 | 24.95 ± 9.62 |
| Apigenin | N/A | 38.99 ± 3.82 | 31.63 ± 10.26 | 35.38 ± 3.98 | 28.12 ± 2.37 | 36.52 ± 5.79 | 32.11 ± 4.13 | 40.46 ± 4 |
| Oseltamivir | N/A | N/A | N/A | N/A | 86.87 ± 7.8 | N/A | 25.37 ± 8.32 | 25.5 ± 8.36 |
| Ribavirin | 57.9 ± 10.54 | 39.87 ± 9.71 | 29.8 ± 6.4 | 36.2 ± 13.7 | 25.94 ± 14.6 | 86.7 ± 9.8 | 24.64 ± 3.1 | 26.2 ± 2.4 |
Data are expressed as mean ± SD (n = 3);
N/A: IC.
Figure 6The network of compound-target-biological process analysis for CYZH.